Tempest Therapeutics Inc (TPST)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TPST
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress the next-generation in vivo CAR-T candidate TPST-4003 through clinical development, including first patient dosing in Q4 2026 and initial clinical data in H1 2027.
Stated as a priority in 2 distinct disclosures including 2026-Q2 and a July 2026 announcement. Management expects first patient dosing for TPST-4003 in Q4 2026 with initial clinical data in H1 2027. No revenue yet; company remains pre-revenue and focused on clinical advancement. The trajectory matches management's stated timeline for clinical development.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The company expects first patient enrollment and dosing to occur in the fourth quarter of 2026.”
Integrate newly acquired dual-targeting CAR-T assets, including TPST-2003, and initiate a registrational study for relapsed/refractory multiple myeloma later in 2026.
Stated as a priority in 2 quarters: 2026-Q1 and 2026-Q2. Management completed the asset acquisition in February 2026 and selected a lead manufacturing partner to support the registrational study initiation later in 2026. Financials show increased operating loss reflecting acquisition-related expenses. The company is delivering on integration and study initiation plans as stated.
“Announced selection of Cincinnati Children’s AGCTC as lead manufacturing partner for TPST-2003 supporting registrational study plans.”
“Announced closing of strategic asset acquisition of new dual-targeting CAR-T assets and plans to initiate registrational study later this year.”
Expand business development capabilities and form strategic partnerships, including appointing a Head of Business Development and collaborating with Senlang Biotechnology.
Stated as a priority in 2 quarters: 2026-Q1 and 2026-Q2. Management appointed a Head of Business Development and executed a strategic partnership with Senlang Biotechnology. These actions demonstrate progress in strengthening business development and partnerships as stated.
“Entered strategic partnership with Hebei Senlang Biotechnology to develop TPST-4003.”
“Announced appointment of Andrew Fang as Head of Business Development to lead global BD efforts.”
Respond to Nasdaq listing compliance issues by restructuring the Board of Directors and addressing stockholders’ equity deficiencies.
Stated as a priority in at least 2 disclosures in 2026. Management responded to Nasdaq compliance issues caused by multiple director resignations by appointing two new independent directors. The company remains in a challenging equity position with a deficit of $1.09 million as of June 30, 2026, indicating ongoing regulatory and governance challenges.
Handle executive departures and appointments to maintain leadership strength and support company growth.
Stated as a priority in at least 2 disclosures in 2026. Management managed executive transitions including CFO resignation and Board appointments. These leadership changes align with stated goals to strengthen leadership amid operational challenges.
Over the trailing year it converted 0.54x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to long-term interest rates, Fed net liquidity, the US dollar, real (inflation-adjusted) rates (low R² over the window).
35 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.